Mebendazole Enhances Chemotherapy and Reprograms Macrophages in Patient Tumor Models
Mebendazole shows modest single-agent cytotoxicity in patient-derived AML, ovarian, colorectal and renal cancer cells, but enhances irinotecan and cisplatin effects. In a mouse CT26 colon cancer model, mebendazole promotes M2→M1 macrophage polarization.
By Sanare Lab · August 12, 2026 · 3 min read
Key Takeaway
A 2026 study in Oncology Reports shows that mebendazole modestly kills patient-derived tumor cells alone, but meaningfully boosts irinotecan and cisplatin in acute myeloid leukemia, ovarian, colorectal and renal cancer cells. In a mouse colon cancer model, mebendazole also reprogrammed tumor-associated macrophages from the pro-tumor M2 state to the anti-tumor M1 state, suggesting immune modulation contributes to its anticancer effect. These findings are preclinical; human clinical data are still needed.
Drug repurposing is one of the most active areas in oncology research. Mebendazole, a well-known anthelmintic, has repeatedly shown anticancer properties in tumor models. A new study published in Oncology Reports in 2026 (doi: 10.3892/or.2025.9014) goes further by testing mebendazole alongside standard chemotherapy drugs in patient-derived cells and a live mouse model.
The researchers used primary cultures of tumor cells taken directly from patients with acute myeloid leukemia (AML), ovarian, colorectal and renal cancers. They also used the murine CT26 colon cancer cell line for both in vitro and in vivo experiments. For anyone following the growing body of evidence on fenbendazole versus mebendazole in cancer, this study adds a new layer: it looks at how mebendazole interacts with real cytotoxic drugs rather than working alone. If you are exploring dosing strategies, our dosing calculator can help estimate body-surface-area adjusted amounts.
Table of Contents
- Study Design and Methods
- Patient-Derived Results: Modest Alone, Stronger in Combination
- Mouse Model: Immune Reprogramming, Not Just Direct Killing
- What This Means for Patients
- Frequently Asked Questions
Study Design and Methods
The team used the fluorometric microculture cytotoxicity assay to measure cell death. For solid tumors and the CT26 line, mebendazole was tested alone and in combination with irinotecan, cisplatin or gemcitabine. In vivo, BALB/c mice bearing CT26 tumors received mebendazole, irinotecan, or both. Tumor growth was tracked, and resected tumors were analyzed by flow cytometry for immune cell infiltration.
Patient-Derived Results: Modest Alone, Stronger in Combination
In patient-derived cells, mebendazole showed modest single-agent cytotoxicity. The AML samples were the most sensitive. When combined with standard cytotoxic drugs, the effect was enhanced, particularly with irinotecan. CT26 cells also showed modest sensitivity to mebendazole, which improved the effect of both cisplatin and irinotecan in vitro.
Mouse Model: Immune Reprogramming, Not Just Direct Killing
In the mouse CT26 colon cancer model, both mebendazole and irinotecan slowed tumor growth individually. However, the combination did not significantly outperform mebendazole alone in this particular setup. The more striking finding came from flow cytometry of the resected tumors: mebendazole promoted macrophage polarization from the M2 (pro-tumor) phenotype to the M1 (anti-tumor) phenotype. This suggests that part of mebendazole's anticancer effect may be mediated through immune modulation of the tumor microenvironment, not solely through direct cytotoxicity.
What This Means for Patients
These are preclinical findings. Patient-derived ex vivo cells and mouse models are important steps, but they do not predict clinical outcomes in humans. The immune-modulation angle is promising because it suggests mebendazole could complement immunotherapy approaches, but randomized human trials are needed to confirm any survival benefit. Patients should not alter their chemotherapy regimens without oncologist guidance.
Frequently Asked Questions
What cancers were tested in this study?
Acute myeloid leukemia (AML), ovarian, colorectal and renal cancer cells were tested ex vivo. The CT26 colon cancer cell line was used for in vitro and in vivo mouse experiments.
Which chemotherapy drugs were combined with mebendazole?
Irinotecan, cisplatin and gemcitabine. Irinotecan showed the strongest enhancement with mebendazole in the patient-derived solid tumor cells.
What is M2 to M1 macrophage polarization?
Macrophages can adopt different states. M2 macrophages typically support tumor growth and suppress immune responses. M1 macrophages attack tumor cells and promote inflammation. Mebendazole shifted the balance toward M1 in the mouse tumors, suggesting an immune-boosting effect.
In Plain Terms
Mebendazole, a deworming pill, was tested on real cancer cells taken from patients and in mice with colon cancer. It did not kill many cancer cells by itself, but it made chemotherapy drugs work better. Surprisingly, it also changed the type of immune cells inside the tumors, turning them from helpers of the cancer into attackers of the cancer. This was only tested in mice and isolated cells, not in human patients, so it is still early research.
Shop Sanare Lab
Lab-tested products referenced in the research above.
180 capsules — 99% purity, laboratory tested
180 capsules
Disclaimer: Links are informational and do not constitute medical advice. No mebendazole product is available; fenbendazole is shown as the related benzimidazole compound.
References
- Mansoori S, Blom K, et al. Characterization of the anticancer effect of mebendazole and its interaction with standard cytotoxic drugs in patient tumor cells ex vivo and in an in vivo mouse model. Oncol Rep. 2026; doi:10.3892/or.2025.9014. PMID: 41201043.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any new treatment or altering your cancer therapy regimen.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.